In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated